Northern Trust Corp increased its holdings in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 19.9% during the second quarter, HoldingsChannel.com reports. The fund owned 191,016 shares of the specialty pharmaceutical company’s stock after buying an additional 31,749 shares during the period. Northern Trust Corp’s holdings in BioDelivery Sciences International were worth $563,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Point72 Asset Management L.P. acquired a new stake in shares of BioDelivery Sciences International during the 2nd quarter valued at about $1,770,000. Royce & Associates LP lifted its stake in BioDelivery Sciences International by 19.1% in the 2nd quarter. Royce & Associates LP now owns 2,200,800 shares of the specialty pharmaceutical company’s stock valued at $6,492,000 after buying an additional 352,200 shares in the last quarter. BlackRock Inc. lifted its stake in BioDelivery Sciences International by 2.7% in the 2nd quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock valued at $3,512,000 after buying an additional 30,991 shares in the last quarter. Bank of Montreal Can purchased a new position in BioDelivery Sciences International in the 2nd quarter valued at about $138,000. Finally, Cortina Asset Management LLC purchased a new position in BioDelivery Sciences International in the 2nd quarter valued at about $5,629,000. Hedge funds and other institutional investors own 53.16% of the company’s stock.

Shares of BioDelivery Sciences International stock opened at $3.63 on Friday. BioDelivery Sciences International, Inc. has a twelve month low of $1.70 and a twelve month high of $4.14. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. On average, research analysts predict that BioDelivery Sciences International, Inc. will post -0.61 earnings per share for the current fiscal year.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $3.72, for a total value of $29,760.00. Following the transaction, the director now directly owns 514,187 shares of the company’s stock, valued at approximately $1,912,775.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 151,039 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now directly owns 520,482 shares in the company, valued at $1,478,168.88. The disclosure for this sale can be found here. Insiders sold a total of 191,200 shares of company stock worth $572,681 over the last ninety days. 13.26% of the stock is currently owned by corporate insiders.

A number of research analysts recently weighed in on BDSI shares. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research note on Friday, August 10th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Wednesday, October 3rd. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 7th. Janney Montgomery Scott raised their price target on shares of BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a research note on Friday, November 2nd. Finally, BidaskClub lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.54.

COPYRIGHT VIOLATION NOTICE: “Northern Trust Corp Has $563,000 Stake in BioDelivery Sciences International, Inc. (BDSI)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/12/08/northern-trust-corp-has-563000-stake-in-biodelivery-sciences-international-inc-bdsi.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Recommended Story: Analyst Ratings

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.